Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
Completed
Chipscreen Biosciences, Ltd.
Phase 1
The purpose of this dose-escalation study is to assess the safety and tolerability of
treatment with Chiauranib administered orally over a range of doses in patients with advanced
solid tumors.
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Terminated
Chipscreen Biosciences, Ltd.
Phase 1
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora
B）、VEGFR/PDGFR/c-Kit、CSF-1R targets.
This clinical trial is studying the efficacy and safety of chiauranib works in treating
patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the
latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical
benefit.
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Completed
Chipscreen Biosciences, Ltd.
Phase 1/Phase 2
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora
B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety
of chiauranib(50mg，QD，PO) works in treating patients with relapsed or refractory ovarian
cancer, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well
as the relevancy of which and clinical benefit.
Phase Ib Study of Chiauranib in Patients With Small Cell Lung Cancer
Unknown status
Chipscreen Biosciences, Ltd.
Phase 1
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases
involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory
microenvironment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
